France: Fight against medical devices and in vitro diagnosis medical devices shortages mechanism currently being discussed in the French Parliament

In brief

The long-awaited implementation in statutory law of the fight against medical devices and in vitro diagnosis medical devices (MD/IVDMD) shortages mechanism is currently being discussed in the French Parliament, in a bill containing various provisions adapting French law to European Union law on diverse topics and particularly in the field of public health ("Draft Bill").


In more detail

The National Agency for the Safety of Medicines and Health Products (ANSM) reported that it has observed an increasing number of MD/IVDMD shortages in recent years that it attributes both to difficulties related to the implementation of the European regulations and those related to the current global economic and geopolitical context destabilizing the usual logistical routes. These shortages concern a wide variety of devices.

Whilst ANSM set up a discretionary procedure to anticipate MD/IVDMD (or risks of shortages) in September 2021, the French legislator is currently working on the implementation of such a mechanism in statutory law.

In France, the stock management of medicinal products is strictly regulated: the marketing authorization holders/French so-called exploitants must comply with a stockpiling obligation, and they must inform ANSM, without delay, of any risk of a supply shortage or any supply shortage of medicinal product of a major therapeutic interest that they could face.

The Draft Bill provides for the implementation of similar obligations for the MD/IVDMD manufacturer or its authorized representative, its importer, or distributor of a medical device (retail sales being excluded). This set of obligations would only concern MD/IVDMDs that are deemed essential, i.e. MD/IVDMDs, the unavailability of which is likely to create a situation of serious risk for the patient in terms of access to healthcare.

For those essential MD/IVDMDs, MD/IVDMD operators would have to respect stock monitoring obligations:

  • Any decision to suspend or cease the marketing of an essential MD/IVDMD, or any knowledge of a fact that could cause the suspension or the ceasing of marketing must be notified to ANSM, at least one year before the foreseeable date
  • In case of a shortage, or risk of shortage of essential MD/IVDMD, the MD/IVDMD operator must implement all useful measures in advance, to avoid this (risk of) shortage and therefore avoid disruption of availability
  • If the shortage is unavoidable, the MD/IVDMD operator must make a declaration to ANSM
  • If the operator fails to meet the above-listed obligations, ANSM may take any action to avoid the shortage of the essential MD/IVDMD

As far as sanctions are concerned, in its current version, the Draft Bill proposes to extend the sanctions applicable to medicinal products stock management obligations for essential MD/IVDMDs.

That being said, this Draft Bill is not binding yet. It has to be debated in Parliament and voted to enter into force. Then, ministerial orders will be expected to further define the scope of those obligations and sanctions.

Copyright © 2023 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.